MedImmune signs deal with SBI Biotech
This article was originally published in Scrip
MedImmunehas signed a licensing agreement with SBI Biotechto develop and commercialise the Japanese company's anti-ILT7 protein for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. SBI will receive an up-front payment as well as milestone payments and royalties on future marketed products. MedImmune has the rights to any resulting product candidates and will be responsible for preclinical and clinical development. It will also have the option to license additional targets resulting from SBI's research activities. Dave Mott, MedImmune's ex-CEO who left the company last July, has joined New Enterprise Associates, a venture capital firm active in the biotechnology field.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.